Medical Condition News

RSS

Adamis acquires prostrate drug candidates from Colby Pharmaceuticals

Adamis Pharmaceuticals Corporation today announced the completion of the acquisition from Colby Pharmaceuticals of the remaining exclusive license agreements relating to two drug product candidates for the treatment of prostate cancer (PCa).

20 Oct 2010

MannKind begins MKC1106-MT Phase 2 trial for advanced melanoma

MannKind Corporation today announced the first patient has been dosed in a phase 2 clinical trial of the novel, investigational cancer vaccine MKC1106-MT. As a part of MannKind's cancer immunotherapy program, this phase 2 study will evaluate the safety, tolerability, immune response and clinical response of MKC1106-MT in patients with advanced melanoma.

20 Oct 2010

Jefferson researchers progress in understanding mechanism behind systemic fibrotic disorder

Scientists from the Jefferson Institute of Molecular Medicine of Thomas Jefferson University are now several steps closer to understanding the mechanism behind a novel systemic fibrotic disorder that affects some patients with renal insufficiency who receive imaging contrast agents for MRI. Two of their studies on the disorder appear together in the November issue of the Annals of Rheumatic Diseases.

20 Oct 2010

Research paves way to understand the mechanism of leptin therapy to improve type 1 diabetes

New findings by UT Southwestern Medical Center researchers suggest a novel role for the brain in mediating beneficial actions of the hormone leptin in type 1 diabetes.

20 Oct 2010

New 3D Body Volume Index measurement calculates obesity risk

A new obesity measurement for the 21st Century, which can help identify individuals at risk of illness such as heart disease, strokes and diabetes, has been officially launched.

20 Oct 2010

Spectral commences pivotal Toraymyxin trial for severe sepsis

Spectral Diagnostics Inc., a Phase III company seeking FDA approval for its lead theranostics product for the treatment severe sepsis and septic shock, today announced initiation of its U.S. pivotal trial of Toraymyxin™, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream, for patients with severe sepsis.

20 Oct 2010

ASBP reviews current rules of prescription medication to treat obesity in Kansas

In response to the alarming increase in the overweight and obese population in Kansas, a representative of the American Society of Bariatric Physicians (ASBP) recently testified to the Kansas State Board of Healing Arts. ASBP is America's oldest and most experienced society devoted to the medical treatment of overweight and obesity and associated health conditions and risks.

20 Oct 2010

New research blames billions in medical costs on obesity

Joint research from Cornell University and Lehigh University finds that nearly 17% of U.S. medical costs can be blamed on obesity.

20 Oct 2010

European Commission grants orphan drug status to OBI-1 for hemophilia treatment

Inspiration Biopharmaceuticals, Inc. announced today that the European Commission has granted orphan drug status for OBI-1 for the treatment of hemophilia.

20 Oct 2010

Long term exposure to air pollution increases risk of severe COPD

Long term exposure to low-level air pollution may increase the risk of severe chronic obstructive pulmonary disease (COPD), according to researcher s in Denmark. While acute exposure of several days to high level air pollution was known to be a risk factor for exacerbation in pre-existing COPD, until now there had been no studies linking long-term air pollution exposure to the development or progression of the disease.

20 Oct 2010

Alexza reacquires U.S. and Canadian rights for Staccato Loxapine from BLS

Alexza Pharmaceuticals, Inc. announced today that it has reacquired the U.S. and Canadian rights for AZ-004 (Staccato® loxapine) from Biovail Laboratories International SRL, a wholly-owned subsidiary of Valeant Pharmaceuticals International, Inc.. AZ-004 is being developed for the rapid treatment of agitation in schizophrenia or bipolar disorder patients.

20 Oct 2010

Researchers to study effectiveness of gamma-tocotrienol on prostate cancer cells

Survival rates of the world's most common cancer might soon be increased with a new vitamin E treatment which could significantly reduce tumour regrowth. Queensland University of Technology (QUT) prostate cancer researchers are leading the fight against a disease which kills 3000 Australian men a year.

20 Oct 2010

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online October 21, 2010).

20 Oct 2010

Anticoagulant Pradaxa receives FDA approval for prevention of stroke in atrial fibrillation patients

The U.S. Food and Drug Administration today approved Pradaxa capsules (dabigatran etexilate) for the prevention of stroke and blood clots in patients with abnormal heart rhythm (atrial fibrillation).

20 Oct 2010

Study finds adipose dysfunction linked to steatosis, necroinflammation in G1 CHC patients

Researchers at the University of Palermo in Italy provide the evidence that a higher visceral adiposity index score-a new index of adipose dysfunction-has a direct correlation with viral load and is independently associated with both steatosis and necroinflammatory activity in patients with genotype 1 chronic hepatitis C (G1 CHC).

20 Oct 2010

Protein hormone inhibits leptin-induced migration of liver cancer cells

A research team from Emory University School of Medicine investigated the role between adiponectin and leptin in obesity-related carcinogenesis. Their findings, published in the November issue of Hepatology, suggest that the protein hormone adiponectin has potential for inhibiting the oncogenic actions of leptin, namely in hepatocellular carcinoma (HCC), and could offer a promising therapy for the disease.

19 Oct 2010

BioMarin announces BMN-111 program for treatment of achondroplasia

BioMarin Pharmaceutical Inc. today announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia. BioMarin plans to file an IND in the fourth quarter of 2011 and to initiate a Phase 1 clinical trial by the first quarter of 2012.

19 Oct 2010

Rexahn announces publication of 3-aryl-1-isoquinolinamines preclinical data

Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of new preclinical data on the development of 3-aryl-1-isoquinolinamines in the European Journal & Medicinal Chemistry.

19 Oct 2010

Pharmacy graduate awarded national recognition for pioneering research in genetics

A young pharmacy graduate has been awarded national recognition for her pioneering research in the field of genetics which has the potential to treat diseases such as cancer and Parkinson's.

19 Oct 2010

ReGen takes exception to FDA CDRH's plan to rescind Menaflex knee implant 510(k) clearance

ReGen Biologics Inc. is taking exception to the FDA's Center for Devices and Radiological Health's (CDRH) Thursday announcement of a plan to rescind the 510(k) clearance of the company's Menaflex knee implant.

19 Oct 2010

Medical Condition News

Adamis acquires prostrate drug candidates from Colby Pharmaceuticals

MannKind begins MKC1106-MT Phase 2 trial for advanced melanoma

Jefferson researchers progress in understanding mechanism behind systemic fibrotic disorder

Research paves way to understand the mechanism of leptin therapy to improve type 1 diabetes

New 3D Body Volume Index measurement calculates obesity risk

Spectral commences pivotal Toraymyxin trial for severe sepsis

ASBP reviews current rules of prescription medication to treat obesity in Kansas

New research blames billions in medical costs on obesity

European Commission grants orphan drug status to OBI-1 for hemophilia treatment

Long term exposure to air pollution increases risk of severe COPD

Alexza reacquires U.S. and Canadian rights for Staccato Loxapine from BLS

Researchers to study effectiveness of gamma-tocotrienol on prostate cancer cells

Ceregene commences enrollment in CERE-120 Phase 2b study for Parkinson's disease

Anticoagulant Pradaxa receives FDA approval for prevention of stroke in atrial fibrillation patients

Study finds adipose dysfunction linked to steatosis, necroinflammation in G1 CHC patients

Protein hormone inhibits leptin-induced migration of liver cancer cells

BioMarin announces BMN-111 program for treatment of achondroplasia

Rexahn announces publication of 3-aryl-1-isoquinolinamines preclinical data

Pharmacy graduate awarded national recognition for pioneering research in genetics

ReGen takes exception to FDA CDRH's plan to rescind Menaflex knee implant 510(k) clearance

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News